Ashley Yeo

Ashley Yeo

Executive Editor, MTI; Medtech Editor, In Vivo

London, UK

Ashley has reported on health care market issues with Citleline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).

Latest from Ashley Yeo

German Medtechs Up The Stakes On Amending Hospital Reform Law

Whoever is handed the health portfolio in Germany’s new coalition government will face demands to amend the recently-enacted hospital and DRGs reform law. The medtech industry has been quick to make the case for change.

Medtech Regulatory System, IDAP And CERSI Top UK MHRA Agenda In March Update

Britain’s medtech system progress, smarter ways of working at the agency and getting smarter AI and digital technologies into circulation for patients, were themes woven through the UK MHRA board’s 18 March meeting.

NHS England Abolition Fits UK Drive To Balance Regulation With Innovation

Centralized decisions and cost savings are targeted in the UK government’s plan to combine much of NHS England with the Department of Health and Social Care. The action will likely divert resources away from health ministry efforts to launch the 10-Year Care Plan, but how else will medtechs be impacted?

UK Life Sciences At The Crossroads: ‘Seize The Chance To Collaborate And Innovate’

A perspective on global healthcare trends and UK opportunities from Yogan Patel, head of life sciences at chartered accountancy MHA, a member firm of Baker Tilley International.

Industry Gives Broad Welcome To Abolition Of NHS England But Needs Time To Weigh Impact

Insight into the knock-on effects on innovation adoption and procurement is keenly awaited by medtechs.

Reinventing Prevention: Milken Institute Foresees Another Route Using Private And Public Funding

New funding mechanisms are required to give more momentum to prevention in the community and thereby relieve pressure on overburdened health care providers like the UK National Health Service. So says Simon Radford, a director at global thinktank the Milken Institute, which sees a solution in more funding for community-level prevention.